Created: 26 June 2020 26 June 2020
Last Updated: 11 August 2021 11 August 2021
Hits: 961 961

June 2020 NewsletterClick on the image to view the full June Newsletter.

Obinutuzumab can cause severe and life-threatening infusion reactions during initial and subsequent infusions. Daclizumab is not approved for use by anyone younger than 18 years old. Among the 58 patients with genotype 1a, 88% developed a NS3 mutation, 78% NS5A mutation, and 67% an NS5B mutation These symptoms can still occur several weeks after you've stopped using Evoclin.